3 6 Ke·2026-01-19 12:35Group 1 - U.S. pharmaceutical companies are increasing pressure on Europe to raise drug prices, with some threatening to stop supplying new drugs if European lawmakers do not comply [1][2] - Pfizer was the first to reach a "most-favored-nation price" agreement with the Trump administration, which has led to increased drug prices in overseas markets [1][2] - As of now, 16 multinational pharmaceutical companies have agreed to lower drug prices in the U.S., including AstraZeneca and Genentech [1] Group 2 - Trump praised these agreements as tools to force Europe to raise drug prices, claiming they have transformed prescription drug pricing in the U.S. to the lowest in the world [2] - Pharmaceutical executives, including Pfizer's CEO Albert Bourla, indicated they would prefer to stop supplying drugs to countries like France rather than lower U.S. prices [2] - Bristol-Myers Squibb previously threatened to halt the launch of a popular schizophrenia drug in the UK unless prices were increased, and the UK has since promised to raise drug prices following an agreement with the U.S. [2] Group 3 - European countries, which have government-led healthcare systems, have historically pressured pharmaceutical companies to accept lower prices, contrasting with the U.S. system that lacks a unified drug price negotiation mechanism [3] - The CEO of Germany's largest public health insurance provider stated that current drug prices in Germany are too high and called for legislative action to reduce spending, particularly on patented drugs [3] - Analysts predict that the ongoing tension may lead to further delays in the launch of new drugs in Europe, with new drugs currently taking about a year longer to reach the European market compared to the U.S. [3]